TY - JOUR
T1 - Endometrial stromal sarcomas: A revision of their potential as targets for immunotherapy
AU - Tuyaerts, Sandra
AU - Amant, Frédéric
PY - 2018
Y1 - 2018
N2 - Endometrial stromal sarcomas are a subtype of uterine sarcomas that are characterized by recurrent chromosomal translocations, resulting in the expression of tumor-specific fusion proteins that contribute to their tumorigenicity. These characteristics make the translocation breakpoints promising targets for immunotherapeutic approaches. In this review, we first describe the current knowledge about the classification of endometrial stromal sarcomas, and their molecular and genetic characteristics. Next, we summarize the available data on the use of translocation breakpoints as immunotherapeutic targets. Finally, we propose a roadmap to evaluate the feasibility of immunologic targeting of the endometrial stromal sarcoma-specific translocations in patients with recurrent disease.
AB - Endometrial stromal sarcomas are a subtype of uterine sarcomas that are characterized by recurrent chromosomal translocations, resulting in the expression of tumor-specific fusion proteins that contribute to their tumorigenicity. These characteristics make the translocation breakpoints promising targets for immunotherapeutic approaches. In this review, we first describe the current knowledge about the classification of endometrial stromal sarcomas, and their molecular and genetic characteristics. Next, we summarize the available data on the use of translocation breakpoints as immunotherapeutic targets. Finally, we propose a roadmap to evaluate the feasibility of immunologic targeting of the endometrial stromal sarcoma-specific translocations in patients with recurrent disease.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85052613804&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30149610
U2 - https://doi.org/10.3390/vaccines6030056
DO - https://doi.org/10.3390/vaccines6030056
M3 - Review article
C2 - 30149610
SN - 2076-393X
VL - 6
JO - Vaccines
JF - Vaccines
IS - 3
M1 - 56
ER -